In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Advertisement
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

Health Technology Assessments And the Trouble With Rare Disease Treatments

To get their gene or cell therapies through health technology appraisals, companies need to agree to gather longer-term evidence, be upfront about what treatments can really deliver and remember to ask for patient input.

Europe Health Technology Assessment

Novartis Strikes Kymriah Outcome-Based Deal With German Insurers

Novartis and German insurers have agreed a payment by outcomes deal for its CAR-T therapy Kymriah.

Europe Germany

Vertex CEO Defends Salary After Company Is Slammed For Orkambi Pricing At UK Hearing

Vertex CEO Jeff Leiden has defended his company’s approach to pricing, as well as his $17m salary, at a heated UK public hearing on access to cystic fibrosis drug Orkambi.

Europe United Kingdom

NHS England, NICE & Vertex Have ‘Forgotten Patients’ In Orkambi Impasse

Vertex, NHS (National Health Service) England, and the health technology appraisal body NICE have forgotten about patients in the impasse over access to cystic fibrosis drug Orkambi, says a patient representative who attended the recent hearing on the price of the drug.

Europe United Kingdom

‘Extreme Outlier’ Vertex Slammed For Orkambi Pricing Approach In England

Vertex has come under fire for its alleged extreme rigidity on pricing for its cystic fibrosis drug in England.

Europe United Kingdom

Dutch Move On Pharmacy Compounding Could Deter Orphan Drug Launches

Medicines prepared in pharmacies are now exempt from patent law in the Netherlands, giving pharmacists greater scope to prepare their own versions of patented medicines.

Europe Netherlands
See All
Advertisement
UsernamePublicRestriction

Register